Imugene Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company specializes in activating the immune system to target and eradicate tumours, leveraging a diverse pipeline of clinical-stage assets and proprietary platform technologies. Key products include B-cell peptide cancer vaccines such as HER-Vaxx and PD1-Vaxx, oncolytic virotherapies like CF33, and an off-the-shelf CAR T cell therapy targeting CD19 for blood cancers. Imugene’s research and development efforts are centred on addressing high unmet medical needs in oncology, with a strategic emphasis on advancing therapies through early clinical trials to establish safety and efficacy. Headquartered in Sydney, Australia, Imugene operates within the biotechnology sector and is listed on the CHI-X Market Australia – Limit Venue, providing investors access to its shares in a competitive and regulated trading environment. The company’s work is supported by a team of international cancer experts with extensive experience in clinical development and commercialization.